Lupin licenses biosimilar Armlupeg to Valorum for U.S. market

Lupin Limited, a global pharmaceutical major, has partnered with Valorum Biologics for the exclusive licensing and commercialization of its biosimilar Armlupeg™ (pegfilgrastim-unne) in the United States. Under the agreement, Valorum will manage the commercialization and distribution of Armlupeg™, while Lupin will handle manufacturing and supply.

Lupin is set to receive an upfront license fee and royalty payments based on net sales. Armlupeg™ is indicated for reducing the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy.

This collaboration aims to expand access to affordable treatment options and strengthen Lupin's presence in the U.S. biosimilars market. Valorum Biologics, a specialized U.S. commercialization partner, brings expertise in regulatory approval, launch, and ongoing commercialization of biopharmaceutical products.